651.23MMarket Cap-5.91P/E (TTM)
12.500High12.050Low50.85KVolume12.200Open12.320Pre Close626.87KTurnover0.14%Turnover RatioLossP/E (Static)52.97MShares17.58052wk High2.81P/B451.61MFloat Cap4.09052wk Low--Dividend TTM36.73MShs Float71.580Historical High--Div YieldTTM3.65%Amplitude3.350Historical Low12.328Avg Price1Lot Size
Stoke Therapeutics Stock Forum
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
In the rapidly evolving world of biotechnology, companies like Stoke Therapeutics are pioneering groundbreaking treatments that could potentially change the lives of patients with severe diseases. The recent buzz surrounding Stoke Therapeutics, particularly their work on an anti-epilepsy drug, STK-001, underscores the transformative potential of RNA-based therapies in addres...
No comment yet